Literature DB >> 8512756

The use of proprietary medicines by patients presenting with peptic ulcer haemorrhage.

J F Marriott1, P A Asquith, C J Shorrock.   

Abstract

1. Medication, social and symptom histories were compared in patients with severe haemorrhage from a peptic ulcer (n = 71) and matched control subjects. Self-medication with proprietary agents was catalogued in addition to therapy prescribed by general medical practitioners. 2. Prior to the bleed, only 4% of ulcer patients had been free of symptoms normally associated with peptic ulceration, whereas 76% of the control group had been asymptomatic. 3. Gastro-irritant proprietary medicines were used regularly by 23% of ulcer patients compared with only 4% of controls. However, proprietary antacids were used chronically by 46% of ulcer patients compared with only 7% of controls. Bicarbonate was the antacid of choice used by 13% of ulcer patients. The odds ratio for the association between development of bleeding peptic ulcer and the use of indigestion remedies was 11.5% (95% CI 1.1, 121). 4. Fifty-one percent of ulcer patients were prescribed agents known to cause gastro-intestinal damage, whereas only 25% of the control group were prescribed similar agents. Only 7% of the control group were prescribed anti-ulcer therapy compared with 37% of those with bleeding ulcer. 5. A large proportion of patients with haemorrhage from a peptic ulcer had had symptoms sufficient to warrant recourse to self-medication with antacids without medical knowledge. Exacerbation of peptic ulcer by self-medication with proprietary products is likely to be of lesser significance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8512756      PMCID: PMC1381680          DOI: 10.1111/j.1365-2125.1993.tb04168.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

Review 1.  Dyspepsia in general practice.

Authors:  C Brown; W D Rees
Journal:  BMJ       Date:  1990-03-31

2.  Effect of non-steroidal anti-inflammatory drugs on dyspeptic symptoms.

Authors:  T M Shallcross; R V Heatley
Journal:  BMJ       Date:  1990-02-10

3.  Changing pattern of admissions and operations for duodenal ulcer.

Authors:  K D Bardhan; G Cust; R F Hinchliffe; F M Williamson; C Lyon; K Bose
Journal:  Br J Surg       Date:  1989-03       Impact factor: 6.939

4.  Value of a centralised approach in the management of haematemesis and melaena: experience in a district general hospital.

Authors:  R A Holman; M Davis; K R Gough; P Gartell; D C Britton; R B Smith
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

5.  Paracetamol and peptic ulcer.

Authors:  D W Piper; J H McIntosh
Journal:  Lancet       Date:  1988-11-19       Impact factor: 79.321

Review 6.  Asymptomatic peptic ulcer disease.

Authors:  R Jorde; P G Burhol
Journal:  Scand J Gastroenterol       Date:  1987-03       Impact factor: 2.423

Review 7.  Long term treatment of duodenal ulcer. A review of management options.

Authors:  G Bianchi Porro; F Parente
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

8.  20 years of hospital admissions for peptic ulcer in England and Wales.

Authors:  D Coggon; P Lambert; M J Langman
Journal:  Lancet       Date:  1981-06-13       Impact factor: 79.321

9.  Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial.

Authors:  T K Daneshmend; C J Hawkey; M J Langman; R F Logan; R G Long; R P Walt
Journal:  BMJ       Date:  1992-01-18

10.  A framework for taking a treatment history.

Authors:  A Herxheimer
Journal:  J R Coll Physicians Lond       Date:  1989-01
View more
  1 in total

1.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.

Authors:  L A García Rodríguez; S Hernández-Díaz; F J de Abajo
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.